Tranexemic Acid (TXA) for Traumatic Brain Injury

​​​​​​​​​​​Overview

Researchers at the University of Washington based at Harborview Medical Center, as part of the Resuscitation Outcomes Consortium, are joining a national study to determine what role tranexamic acid plays in decreasing mortality for patients with traumatic brain injuries. Eileen Bulger, MD is principal investigator for this clinical study.

Tranexamic acid is an FDA-approved drug commonly used to treat excessive bleeding by blocking disintegration of blood clots. The study is the first to examine the use of tranexamic acid in patients with head trauma.

More than 50,000 people in the United States die annually from traumatic brain injury, and it is the leading cause of death in trauma patients. The researchers hope this study will shed light on whether a timely dose of tranexamic acid could reduce that statistic.

Pre-hospital providers will administer the drug as soon as possible after stabilizing a patient they suspect has a traumatic brain injury. Each of the 1,002 patients enrolled at one of 10 locations in the United States and Canada will receive either one gram of the drug before hospital arrival and one after, or two grams before arrival and none after. Participants in the control group will be given the standard saline treatment.

The researchers are seeking feedback from the community regarding the conduct of this study. There is additional information in the attached power-point presentation.  There is also a short survey attached where you can add your feedback.  Additionally, individuals can opt out of participating in the study by wearing a bracelet that reads "NO STUDY." The bracelet indicates that, should you be injured, medical care providers will exclude you from the research. If you have questions or would like additional information about this study please contact the Research Team at 206.744.7724 or email pklotz@uw.edu.

We will attempt to return e-mails and calls during business hours. We will not keep any personal information you provide, nor will we share any of your personal information with anyone.

Seattle enrollment begins this fall.

​For more information, watch a video Q&A with Dr. Eileen Bulger, read the news release, and view a presentation.

​Catalyst CC survey: https://catalyst.uw.edu/webq/survey/pklotz/237636​​​